However, a focused analysis of the 51 IPMN cases showed that a signature of eight lncRNAs (ADARB2-AS1, ANRIL, GLIS3-AS1, LINC00472, MEG3, PANDA, PVT1, and UCA1) discriminated between the malignant and benign IPMNs (p < 0.05) (Table 3; Fig. 1). Here, GLIS3 is linked to pancreatic intraductal papillary-mucinous neoplasm.